The discovery of ICI, such as anti‐PD‐1, anti‐PD‐L1, and anti‐CTLA4, allowed the development of treatments that can significantly generate antitumor activity, especially in tumors with high tumor mutational burden (TMB). This evidence concerns the gene CTLA4 and neoplasm.